Other: Siponimod ( DrugBank: Siponimod )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04933552 (ClinicalTrials.gov)	December 15, 2021	18/6/2021	Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzen ...	Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzen ...	Multiple Sclerosis	Other: Siponimod	Novartis Pharmaceuticals	NULL	Recruiting	N/A	N/A	Female	867		United States
2	NCT04895202 (ClinicalTrials.gov)	November 19, 2021	17/5/2021	Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study	Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patient ...	Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity	Other: Siponimod	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	60		Switzerland
3	NCT04926818 (ClinicalTrials.gov)	October 5, 2021	14/6/2021	Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Mu ...	A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of ...	Multiple Sclerosis (MS)	Drug: Fingolimod;Drug: Ofatumumab;Drug: Siponimod;Other: Fingolimod placebo;Other: Siponimodplacebo; ...	Novartis Pharmaceuticals	NULL	Recruiting	10 Years	17 Years	All	180	Phase 3	United States;Australia;Austria;Belgium;France;Germany;India;Latvia;Mexico;Poland;Portugal;Russian F ...

First Previous1Next Last